Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

Dr. Jacob D. Soumerai presents updated data from the BGB-11417-101 study, highlighting the high efficacy, tolerability, and sustained minimal residual disease clearance achieved with the novel combination of sonrotoclax and zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia.